Azenosertib

N/A

Report date: 2026/05/23 20:00:57
NMEFirst In Class

Base Information

Drug NameAzenosertib
Drug Alias NameKP-2638ZN-c3
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine/threonine-protein kinase WEE1 inhibitors
TargetsSerine/threonine-protein kinase WEE1
Therapy Area/IndicationsSolid tumoursuterine serous carcinomaUterine Neoplasms +[21] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumBosnia and HerzegovinaBulgaria +[18] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesZentalis Pharmaceuticals LLC
China Registration ClassN/A

Develop Information

Active CompaniesCaris Life SciencesThe Netherlands Cancer InstituteZeno Pharmaceuticals Inc +[7] 
Inactive CompaniesZentalis Pharmaceuticals IncOhsu Knight Cancer InstitutePfizer Inc +[7] 
Active IndicationsSolid tumoursUterine NeoplasmsFallopian Tube Neoplasms +[14] 
Inactive Indicationsuterine serous carcinomaLung NeoplasmsTriple Negative Breast Neoplasms +[7] 

Other Information

ATC CodeN/A
Related LinksN/A